scholarly journals Severity of COVID-19 in bacillus Calmette-Guérin vaccinated population

2021 ◽  
Vol 10 (3) ◽  
pp. 276
Author(s):  
Iffat Khanum ◽  
Lokesh Kumar ◽  
Safia Awan ◽  
Bushra Jamil
Keyword(s):  
Bacillus Calmette Guerin

1570: Combined Mitomycin C and Hyperthermia (SYNERGO) for Patients with Superficial Bladder Cancer (SBC) after Bacillus Calmette-Guerin (BCG) Failure

2007 ◽  
Vol 177 (4S) ◽  
pp. 519-519
Author(s):  
Ofer Nativ ◽  
Renzo Colombo ◽  
Dov Engelstein ◽  
Ofer N. Gofrit ◽  
Thomas Akkad ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mitomycin C ◽  
Superficial Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Bcg Failure

In silico ADME, Bioactivity and Toxicity Parameters Calculation of Some Selected Anti-Tubercular Drugs

2016 ◽  
Vol 6 (6) ◽  
pp. 77 ◽  
Author(s):  
Shashank Shekhar Mishra ◽  
Chandra Shekhar Sharma ◽  
Hemendra Pratap Singh ◽  
Harshda Pandiya ◽  
Neeraj Kumar
Keyword(s):  
Antibiotic Resistance ◽  
In Silico ◽  
Bacillus Calmette Guerin ◽  
Computational Investigation ◽  
Pharmacological Profile ◽  
In Silico Toxicity ◽  
Is Development ◽  
Potent Drug ◽  
Minimal Resistance ◽  
Parameters Calculation

Tuberculosis, one of the most frequent infectious diseases, is caused by a mycobacterium tuberculosis bacteria and it infects several hundred million people each year, results in several million deaths annually. Because there is development of antibiotic resistance, the disease becomes incurable. So, in the absence of effective and potent drug with minimal resistance problems, the mortality rate increases annually. In this computational investigation, we performed In-silico ADME, bioactivity and toxicity parameters calculation of some selected anti-tuberculosis agents. To design a new molecule having good pharmacological profile, this study will provide the lead information.Key Words: Tuberculosis (TB), Bacillus Calmette-Guerin vaccine, TPSA, In Silico toxicity

Immunobiological Markers in Prophylaxis Post-exposure with Single Dose of Rifampicin and BCG Vaccine in Contacts of Multibacillary Leprosy Cases: Study Protocol (Preprint)

2020 ◽  
Author(s):  
Camila Massae Sato ◽  
Omar Ariel Espinosa Domínguez ◽  
Gutembergue Santos de Sousa ◽  
Fabiane Verônica da Silva ◽  
Roberta Olmo Pinheiro ◽  
...  
Keyword(s):  
Single Dose ◽  
Bcg Vaccine ◽  
Reference Laboratory ◽  
Serological Response ◽  
Bacillus Calmette Guerin ◽  
Prophylactic Measure ◽  
Mato Grosso ◽  
Household Contacts ◽  
Ifn Γ ◽  
Multibacillary Leprosy

BACKGROUND Leprosy contacts are sensitive indicator of the magnitude of severity, and a high risk for infection and disease, especially if the individuals are exposed to the bacillus with multibacillary cases, which reinforces the need for chemoprophylactic measures, such as the use single-dose rifampicin (SDR) combined with BCG vaccine. OBJECTIVE Our study will analyze the serological response of anti-NDO-LID, HO-1/HMOX and serum IFN-γ concentration as a prophylactic measure after the use of single-dose rifampicin (SDR) combined with the Bacillus Calmette-Guérin vaccine (BCG) among multibacillary leprosy household contacts. METHODS Intervention study based on a prospective cohort of household contacts of new cases of multibacillary leprosy diagnosed and registered in the Information System on Diseases of Compulsory Declaration (SINAN – Sistema de Informação de Agravos de Notificação) and residents in the municipalities of Cuiabá and Cáceres, Mato Grosso, in the years 2019 and 2020. Contacts with no signs and symptoms compatible with the disease of the intervention group will receive single-dose rifampicin (SDR) combined with BCG vaccine and will be compared to the control group. The follow-up of the cohort will last 12 months. The analyses of the anti-NDO-LID, HO-1/HMOX and serum concentration of IFN-γ tests as immunological markers before, 6 and 12 months after the intervention will be conducted in a reference laboratory (FIOCRUZ). RESULTS The study is still recruiting participants and is expected to be completed in September 2020. CONCLUSIONS Our study seeks to analyze the response of anti-NDO-LID, HO-1/HMOX tests and serum IFN-γ concentration as a prophylactic measure after the use of single-dose rifampicin (SDR) combined with the Bacillus Calmette-Guérin vaccine (BCG) in home contacts of multibacillary leprosy cases. CLINICALTRIAL Brazilian Registry of Clinical Trials (ReBEC), RBR-6yg2z9. Retrospectively registered on 3 de Out. de 2019.

Bacillus Calmette-Guerin (BCG) vaccine for preventing Buruli ulcer

2002 ◽  
Author(s):  
R Phillips ◽  
H Ejere ◽  
C Preston ◽  
Asiamah ◽  
E
Keyword(s):  
Buruli Ulcer ◽  
Bcg Vaccine ◽  
Bacillus Calmette Guerin
Sign in / Sign up

Export Citation Format

Share Document